Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3β (GSK-3β) inhibitors: 3D-QSAR, virtual screening, docking, MM/GBSA, EC, MD simulation studies
Molecular Diversity · 2025-10 · 29 (5) · 4177-4201
DOI: 10.1007/s11030-024-11026-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, online erschienen am 19.11.2024. Verfasst von Desu Gayathri Niharika und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Sciences, National Institute of Technology Andhra Pradesh, Tadepalligudem, Andhra Pradesh, 534101, India. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Quantitative Structure-Activity Relationship, Molecular Docking Simulation, Molecular Dynamics Simulation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Glycogen synthase kinase-3β (GSK-3β) has emerged as a crucial target due to its substantial contribution in various cellular processes. Dysfunctional GSK-3β activity can lead to ion channel disturbances, sustain abnormal excitability, and contribute to the pathogenesis of epilepsy and other GSK-3β-related disorders. A set of 82 pyrazole analogs was utilized to study its structural features using a three-dimensional quantitative structure-activity relationship (3D-QSAR), virtual screening, molecular docking, and molecular dynamics. The QSAR model, validated using internal and external methods, demonstrated robustness with a high correlation coefficient r2training = 0.99, cross-validation coefficient q2 = 0.79, r2test = 0.69, and r2external = 0.74. The "Average of Actives" in the Activity Atlas model identified 17 molecules as active. Subsequent pharmacophore-based virtual screening of 17 actives yielded 70 compounds, which were selected as the prediction set to determine the potential GSK-3β inhibitors. Docking studies pinpointed compound P66 as the promising lead compound, with a docking score of - 10.555 kcal/mol. These findings were further supported by electrostatic potential (ESP), electrostatic complementarity (EC), and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) analyses. Furthermore, a 500 ns molecular dynamics (MD) simulation confirmed the structural and conformational stability of the lead complex throughout the simulation period. As a result, this study suggests that compound P66 holds the potential to be a potent lead candidate for the inhibition of GSK-3β, offering a novel therapeutic approach for GSK-3β related disorders, including epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Sciences, National Institute of Technology Andhra Pradesh, Tadepalligudem, Andhra Pradesh, 534101, India.
- Department of Chemistry, School of Sciences, National Institute of Technology Andhra Pradesh, Tadepalligudem, Andhra Pradesh, 534101, India. amarendar@nitandhra.ac.in.
Zitieren
APA
Niharika, D. G., Salaria, P., & Reddy, M. A. (2025). Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3β (GSK-3β) inhibitors: 3D-QSAR, virtual screening, docking, MM/GBSA, EC, MD simulation studies. Molecular Diversity, 29(5), 4177-4201. https://doi.org/10.1007/s11030-024-11026-0
Vancouver
Niharika DG, Salaria P, Reddy MA. Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3β (GSK-3β) inhibitors: 3D-QSAR, virtual screening, docking, MM/GBSA, EC, MD simulation studies. Molecular Diversity. 2025;29(5):4177-4201. doi:10.1007/s11030-024-11026-0
BibTeX
@article{Niharika2025,
author = {Niharika, Desu Gayathri and Salaria, Punam and Reddy, M Amarendar},
title = {Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3β (GSK-3β) inhibitors: 3D-QSAR, virtual screening, docking, MM/GBSA, EC, MD simulation studies},
journal = {Molecular Diversity},
year = {2025},
volume = {29},
number = {5},
pages = {4177--4201},
doi = {10.1007/s11030-024-11026-0}
}
EUVIMED